Could There Be Opportunity in Novavax Stock Right Now? Analyst Weighs In
Yahoo! Finance
Bringing a Covid-19 vaccine to market is proving extremely tricky for Novavax (NVAX). After the biotech’s proposed vaccine delivered excellent results in late-stage trials which matched the standard of other approved vaccines, the company has continually delayed filing for approval in various regions including the US. The story took another wrong turn on Wednesday when a Politico article cited “anonymous sources” who claimed Novavax’ manufacturing problems ran deeper than previously thought; the
Continue Reading